Noradrenalin vs Terlipressin in Hepatorenal Syndrome

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome

Clinical Trial Description

Hepatorenal syndrome (HRS) is a major complication of cirrhosis; it is characterized by functional renal failure and poor prognosis. Arterial dilation is a key pathogenic event of HRS, leading to reduction of the effective blood volume, homeostatic activation of vasoactive systems and renal vasoconstriction with decrease in renal blood flow. The clinical signs of HRS vary depending on the clinical pattern. HRS type 1 is characterized by a rapidly progressive renal failure; HRS type 2 by a moderate and more stable renal failure. HRS type 1 has a very poor short term prognosis, with a median survival of only about 2 weeks; patients with HRS type 2 have a median survival of about 6 months. The management of HRS still constitutes a major challenge. Liver transplantation is the ideal treatment, but it has important inherent drawbacks, such as the organ shortage and the time needed to perform the transplant, that is too long to consent the survival of these patients. The management of HRS has focused on improving renal function, thus extending patients survival and allowing the performance of the liver transplant. In the last years, remarkable results have been obtained using vasoconstrictor drugs. By improving the effective blood volume, vasoconstrictors induce the suppression of homeostatic vasoactive systems and increase renal blood flow and glomerular filtration rate.Among vasoconstrictors, terlipressin, a V1 vasopressin agonist, has currently the best efficacy pedigree. However, it is expensive and is not available in many countries, including North America. More recently, it was suggested that alpha-adrenergic drugs such noradrenalin and midodrine may be also effective in HRS. Noradrenalin would have the potential advantage of wider availability and of lower cost. The current prospective randomized study was undertaken to assess the efficacy and safety of noradrenalin vs terlipressin in patients with HRS. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00370253
Study type	Interventional
Source	University of Turin, Italy
Contact
Status	Completed
Phase	Phase 3
Start date	September 2006
Completion date	September 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00359853` - Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis	Phase 4
Completed	`NCT01436500` - Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients	Phase 2
Completed	`NCT01143246` - A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin	Phase 3
Recruiting	`NCT05346393` - HRS-AKI Treatment With TIPS in Patients With Cirrhosis	N/A
Terminated	`NCT00742339` - Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome	Phase 2/Phase 3
Terminated	`NCT00734136` - Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome	N/A
Recruiting	`NCT06095440` - A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
Completed	`NCT02097784` - Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury	N/A
Recruiting	`NCT04898010` - The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I	N/A
Recruiting	`NCT05875948` - Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome	Phase 2
Completed	`NCT04416282` - Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.	N/A
Recruiting	`NCT02049125` - Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis	N/A
Completed	`NCT00764049` - Single Pass Albumin Dialysis in Patients With Cirrhosis	Phase 1/Phase 2
Completed	`NCT00089570` - Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1	Phase 3
Withdrawn	`NCT01587222` - Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure	Phase 2
Recruiting	`NCT02489864` - The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure	Phase 4
Recruiting	`NCT02434445` - Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients	N/A
Completed	`NCT02770716` - Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1	Phase 3
Completed	`NCT05387811` - International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
Withdrawn	`NCT04048707` - Angiotensin 2 for Hepatorenal Syndrome	Phase 2